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STUDY QUESTION: What is the effect of endometriosis compared to unexplained subfertility on live birth rate in women undergoing IVF
and embryo transfer (ET)?
SUMMARY ANSWER: Endometriosis decreases live birth rate in women undergoing IVF-ET treatment, particularly with increasing sever-
ity of the disease.
WHAT IS KNOWN ALREADY: Endometriosis affects up to 50% of women seeking fertility treatment and is known to reduce fecundity.
There remains a debate as to effects of endometriosis on the outcomes of IVF treatment, with live birth being a secondary outcome or not
reported in most studies.
STUDY DESIGN, SIZE, DURATION: A retrospective cohort study analyzing data of IVF treatment cycles from January 2000 to
December 2014 was carried out.
PARTICIPANTS/MATERIALS, SETTING, METHODS:Women with endometriosis (n = 531) and women with unexplained subferti-
lity (n = 737) undergoing a first cycle of IVF-ET in a tertiary fertility treatment center were included in the study. The primary outcome was
live birth. Other outcome measures were response to ovarian stimulation, embryo development and implantation rate. Bivariate and multi-
variate logistic regression analysis was performed and differences compared using Chi squared test of Student’s t-test as appropriate.
MAIN RESULTS AND THE ROLE OF CHANCE:Women with endometriosis had 24% less likelihood of a live birth when compared to
those with unexplained subfertility [odds ratio (OR) 0.76 (95% CI, 0.59–0.98) P = 0.035]. This effect became more apparent with increasing
severity of endometriosis. Using multivariable logistic regression analysis, the trend for lower live birth rate remained but did not reach statis-
tical significance [adjusted OR 0.76 (95% CI 0.56–1.03), P = 0.078]. Women with endometriosis were as likely as those with unexplained sub-
fertility to have a singleton live birth when two embryos were transferred as opposed to a single ET [OR 1.38 (95% CI 0.73–2.62), P = 0.32
and OR 3.22 (95% CI 1.7–6.05), P = 0.0003, respectively]. Compared to women with unexplained subfertility, those with endometriosis had
fewer oocytes retrieved [(10.54 (95% CI 10.13–0.95) and 9.15 (95% CI 8.69–9.6), respectively], lower blastocyst transfer [OR 0.24 (95% CI
0.12–0.5), P = 0.0001] and a significantly reduced implantation rate [OR 0.73 (0.58–0.92), P = 0.007].
LIMITATIONS REASONS FOR CAUTION: The study is limited by a retrospective design. By limiting the study to a single ET cycle, it
was not possible to assess the cumulative outcome including use of all frozen embryos.
WIDER IMPLICATIONS OF THE FINDINGS: Endometriosis has similar phenotypes among women in different populations and would
be expected to have a similar effect on fertility. These results are therefore generalizable to other populations of women.
STUDY FUNDING/COMPETING INTEREST(S): None.
TRIAL REGISTRATION NUMBER: Not applicable.
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Introduction
Endometriosis is a chronic inflammatory condition characterized by
presence of ectopic endometrial glands and stroma that respond to
ovarian steroid hormone action (de Ziegler et al., 2010). Commonly,
symptoms present during the reproductive years, being most wide-
spread at 25–35 years of age, and with an estimated prevalence of ~-
5–10% women of reproductive age (Macer and Taylor, 2012).
The association between endometriosis and infertility is well recog-
nized; ~25–50% of infertile women are diagnosed with endometriosis
and ~30–50% of endometriosis patients are thought to suffer from
infertility (Missmer et al., 2004). Yet, the possible mechanisms of
endometriosis-associated infertility remain only poorly understood.
ART using IVF/ET is a well-established and effective technique in the
management of infertility for a variety of different causes (Van Voorhis,
2007). However at present, it is unclear whether endometriosis nega-
tively impacts on the outcomes of IVF and this issue remains highly
debated (Barnhart et al., 2002; Harb et al., 2013).
Most studies looking at this matter were conducted more than a decade
ago, since when the techniques for IVF have evolved and changed, with
improvements made to clinical protocols and laboratory techniques.
Consequently, the findings of previous studies looking at IVF and endomet-
riosis may not represent the current state of practice. Additionally, while
live birth rate is considered the most important ART outcome, this has not
been the primary outcome measure in previous studies. When assessed,
live birth rate had tended to be a secondary outcome, and studies lacked
sufficient statistical power to evaluate the association (Barnhart et al., 2002;
Harb et al., 2013). As a result, it remains unclear whether women with
endometriosis have compromised live birth rate following IVF treatment.
This study aimed to assess the impact of endometriosis on live birth
rate in women undergoing their first IVF cycle compared to those with
unexplained subfertility. Secondary outcome measures included
response to controlled ovarian stimulation (COS) as assessed by total
dose of gonadotrophins, duration of stimulation, number of mature
oocytes retrieved, fertilization rate, blastocyst development, ongoing
pregnancy, miscarriage and ectopic pregnancy rates.
Materials andMethods
We undertook a comprehensive cohort study by analyzing the data of
patients who completed fertility treatment. These were data routinely col-
lected during the course of a patient’s clinical care that had been electron-
ically stored since 1987 in a database (Paradox®, Borland, Scott Valley,
CA, USA). To avoid heterogeneity, we only included data from partici-
pants who had undergone their first cycle of ART at one site, Oxford
Fertility, between January 2000 and December 2014 (Fig. 1). We com-
pared the treatment data for two cohort groups, which are women with
endometriosis and those with unexplained subfertility. All women analyzed
had a diagnostic laparoscopy performed during work-up investigations for
subfertility in a UK National Health Service secondary care hospital prior
to referral for IVF/ICSI treatment. In the endometriosis group, the distri-
bution between different disease stages (defined according to the revised
American Society of Reproductive Medicine (r-ASRM) classification
(ASRM, 1997) was as follows; minimal (26.5%), mild (21.5%), moderate
(24.9%) and severe (27.1%) disease. Appropriate approval was obtained
from the University of Oxford, Central University Research Ethics
Committee (MSD 892) to conduct the study.
Definition and selection of exposed and non-
exposed participants
Patients in the exposed group were defined as women who had endometri-
osis confirmed and staged at laparoscopy prior to starting IVF treatment
(ASRM, 1997). Women with an ultrasound diagnosis of ovarian endometrio-
ma would also have had laparoscopy and endometriosis staging. Ultrasound
features of ovarian endometrioma included unilocular or multi-locular cyst
with ground-glass appearance and no vascular papillary projections. We did
not collect information on the interval between the diagnosis of endometri-
osis and start of IVF treatment. Those in the non-exposed group were
defined as women with confirmed ovulatory cycles with mid-luteal progester-
one of at least 16 pmol/l, patent Fallopian tubes demonstrable with dye test
at laparoscopy and no evidence of endometriosis on laparoscopy, confirming
a diagnosis of unexplained subfertility. Those with multiple diagnoses, severe
male factor subfertility, undergoing donor ART treatment, choosing to freeze
embryos or returning for a subsequent cycle were excluded. We also
excluded cases of treatment protocols other than the long GnRH agonist.
WHATDOES THIS MEAN FOR PATIENTS?
This study looks at the impact endometriosis has on live birth rates after IVF and compares the chances of success of women who have endometri-
osis with those who have unexplained infertility. The researchers looked back over the data from treatment cycles of women having their first IVF
cycle at one clinic over a 14-year period.
Endometriosis affects up to half of women having fertility treatment. It is a condition where tissue similar to the womb lining is found elsewhere
in the pelvic area. Endometriosis is known to reduce fertility, but there has been some debate as to whether it affects the chances of getting preg-
nant with treatment. Some of the studies which have investigated this were carried out some time ago and the techniques used in IVF have
changed.
The researchers found that endometriosis does have an impact on the chances of successful fertility treatment, and that the more severe the
endometriosis is, the more it reduces the likelihood of a successful outcome. The study suggests that more research is needed to find techniques
to help overcome this.
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Sample size calculation
It was estimated that the live birth rate in the unexplained subfertility group
would be 30% (Harb et al., 2013). To detect 20%, relative risk difference
between the two groups, we determined that a sample size of 472 partici-
pants would have 90% power with a significance threshold of 5% (http://
www.openepi.com/SampleSize/SSCohort.htm). We included all the 531
records of confirmed endometriosis and 737 records for the unexplained
subfertility in the study period.
Treatment protocol
The standard IVF treatment for the study was the long GnRH agonist proto-
col, as described previously, using either Buserelin; Suprefact®; Aventis
Pharma, Kent, UK; or Nafarelin; Synarel®; Pharmacia, Milton Keynes, UK
(Swanton et al., 2010). Gonadotrophin stimulation with Gonal-F®; Serono
Pharmaceuticals Ltd., Feltham, UK, Puregon® Organon Laboratories Ltd.,
Hoddesdon, UK, or Menopur® Ferring Pharmaceuticals Ltd., West
Drayton, UK was started at a daily dose ranging from 150 to 375 IU depend-
ing on patient characteristics including age, early follicular phase FSH, antral
follicle count and BMI. When at least three leading follicles measuring
≥18mm were seen on ultrasound scan the trigger injection of hCG 6500 IU
(Ovitrelle®; Serono Pharmaceuticals Ltd., Feltham, UK) was administered,
followed 37 h later by oocyte retrieval. Depending on sperm parameters fol-
lowing preparation on the day of oocyte retrieval, fertilization was achieved
either by conventional IVF or ICSI (Jones et al., 2012). ET was performed
between Days 2 and 5 of development depending on morphological assess-
ment and the woman’s age (Cutting et al., 2008). Criteria for blastocyst cul-
ture were the presence of two top quality embryos on Day 3 in women
younger than 38 years and three top quality embryos for women aged 38
years and older. Top quality embryos were defined as having between 6 and
10 blastomeres of regular size and <20% fragmentation. All embryos
reaching blastocyst stage were considered for transfer regardless of grade.
Standard practice was the transfer of up to two embryos.
Luteal support was initiated 1 day after oocyte retrieval with 800 mg
micronized progesterone (Cyclogest®; Shire Pharmaceuticals Ltd.,
Basingstoke, UK) administered vaginally in two divided doses daily and
continued for 14 days, when a urine pregnancy test was taken. If pregnant,
luteal support continued until 8 weeks of pregnancy when a transvaginal
ultrasound scan was arranged to confirm a clinical pregnancy, detected by
the presence of fetal heart activity. Women were then discharged from
the care of the IVF unit back to their general practitioner and midwife for
follow-up in accordance with national guidelines (National Collaborating
Centre for Women’s and Children’s, 2008). Requirements of the Human
Fertilisation and Embryology Authority ensured recording of comprehen-
sive pregnancy outcome and birth data.
Outcomemeasures
The primary outcome measure was live birth rate per transfer, defined as live
birth at ≥24 weeks of gestation. We also analyzed the cumulative dose of
gonadotrophin used for COS, number of days of stimulation, number of mature
metaphase II oocytes (MII), fertilization rate (defined as number of normally fer-
tilized oocytes divided by total number of oocytes retrieved), blastocyst transfer
rate (number of cycles reaching blastocyst transfer), clinical pregnancy rate
(number of patients with confirmed pregnancy on ultrasound scan divided by
patients with positive pregnancy test) and miscarriage rate (defined as preg-
nancy loss prior to viability scan and including those confirmed on ultrasound
scan up to ≤23+6 weeks of gestation) and number of ectopic pregnancies.
Statistical analysis
Bivariate associations for categorical variables between the outcomes and
identified risk factors were evaluated using a Chi-square or Fisher’s exact
Non-exposed  
(n = 5223)
Endometriosis diagnosis 
( n= 2749)  
Retrieval from Database 
Jan 2000 – Dec 2014 
Analysis endometriosis
(n = 531)
Analysis unexplained 
(n = 737) 
Exclusions unexplained
Unverifiable diagnosis 
Multiple factor infertility 
Severe male factor 
Previous IVF treatment 
n = 4486
Exclusions endometriosis
Unverifiable diagnosis 
Multiple factor infertility 
Severe male factor 
Previous IVF treatment 
n = 2218
Figure 1 Flow diagram showing data retrieval, verification and selection of the cases (endometriosis) and controls (unexplained).
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test as appropriate. The Students t-test was used for continuous variables
to compare mean differences between two groups in the outcomes.
Following univariate analysis, independent variables were incorporated
into a multivariable logistic regression model using backward and stepwise
procedure. The variables included age, baseline FSH, endometriosis stage,
number of mature oocytes and development stage at ET. All statistical ana-
lysis was performed in statistical software STATA® version 12 (College
Station, TX, USA). A P-value < 0.05 was considered statistically significant.
Results
Baseline characteristics
Baseline characteristics are shown in Table I. Women with endometri-
osis (exposed group) were younger compared to those with unex-
plained subfertility with a median age 35 years (range 23–44) and 36
years (range 19–44), respectively, P < 0.0001. Compared with the
unexplained subfertility group, women with endometriosis had a
median FSH 6.7 IU/ml (2.2–17.6) and 6.3 IU/ml (1.5–15.4), P = 0.53,
respectively. Within the grades of endometriosis, the proportion of
women with FSH >10 IU/ml was equally distributed, however this
was higher than in women with unexplained subfertility, P = 0.03.
There was no statistically significant difference in the duration of sub-
fertility between the two groups as well as the history of a previous
birth. Male partners of women unexplained subfertility had a higher
sperm concentration 74.8 million/ml (95% CI, 70–79.7) compared to
those with endometriosis 66.6 million/ml (95% CI, 62.5–70.8), how-
ever this was not clinically significant.
Outcome parameters
Table II shows comparisons of the treatment cycle characteristics
between women in the endometriosis and unexplained subfertility
groups. Overall, women with endometriosis required a higher total
dose of gonadotrophin for ovarian stimulation for a comparable dur-
ation compared to those with unexplained subfertility. Conversely,
compared with the unexplained subfertility group, women with endo-
metriosis had one less mature oocyte and two less total oocytes col-
lected at oocyte retrieval. There was, however, no statistically
significant difference in the percentage fertilization rate between the
two groups. In terms of embryo development, due to variable embryo
development and grading we analyzed the treatment cycles according
to whether they reached blastocyst transfer rather than the propor-
tion of embryos reaching blastocyst development. There were signifi-
cantly fewer cycles reaching the blastocyst transfer in women with
endometriosis compared to those with unexplained subfertility.
Table III shows the bivariate analysis of treatment outcomes
between women with endometriosis and those with unexplained sub-
fertility. Women with endometriosis were 24% less likely to have a live
birth compared to those without endometriosis [OR 0.76 (95% CI
0.59–0.98), P = 0.035]. The odds of a live birth in women with endo-
metriosis decreased with endometriosis disease severity compared to
those with unexplained subfertility (Score test for trend of odds P =
0.008) (Table IV). However, using a stepwise multivariable logistic
regression analysis and correcting for age, baseline FSH, endometriosis
stage, maturity of retrieved oocytes and ET day, this difference was no
longer maintained, [adjusted OR 0.76 (95% CI 0.56–1.03), P = 0.08]
(data in the explanatory text of Table III). Women with endometriosis
were less likely to achieve a positive pregnancy test when compared
to those with unexplained subfertility [OR 0.65 (0.53–0.8), P <
0.0001] (Table III). There was, however, no significant difference in
the clinical pregnancy rate between the two groups.
We sought to explore the chance of achieving a live birth against the
number of embryos transferred by comparing single versus double ET
(Table III). Using descriptive statistics, there was no statistically signifi-
cant difference in the chance of achieving a singleton live birth with
double ET in either the endometriosis or unexplained subfertility
groups [OR 0.72 (0.38–1.36), P = 0.32, however, with single ET the
chance of achieving a singleton live birth was significantly lower in the
endometriosis group [OR 0.31 (0.16–0.58)), P = 0.0002]. This was
unsurprising as this group was more likely to achieve blastocyst
transfer.
Discussion
The association between endometriosis and infertility has been known
for many years, even though the mechanisms are only poorly under-
stood and remain largely speculative. However, the effect of endomet-
riosis on outcomes of infertility treatment using ART continues to be a
subject of debate and interest (Dunselman et al., 2013). Our study
demonstrates that women with endometriosis undergoing IVF treat-
ment have a lower live birth rate when compared to those with unex-
plained subfertility, this effect being greater with increasing disease
severity. Similarly, other outcome parameters were also compromised
in women with endometriosis when compared to women with unex-
plained subfertility. Despite requiring a comparable duration of time
for COS, women with endometriosis compared with those with unex-
plained subfertility were given a higher total dose of gonadotrophin yet
still produced fewer total and mature oocytes. Despite having similar
oocyte fertilization rates, women with endometriosis had fewer
blastocyst transfer cycles compared to women with unexplained sub-
fertility. This observation was surprising as women with endometriosis
were younger than those with unexplained subfertility with both
groups having a comparable ovarian reserve.
These observations confirm in a large cohort using modern IVF
methods the earlier trends noted from smaller studies as well as
national databases (Barnhart et al., 2002; Harb et al., 2013; Senapati
et al., 2016). We believe this is the first study to look at live birth as
the primary outcome measure using a large sample size with appropri-
ate power calculation. Live birth rate is the ideal outcome variable for
ART (Maheshwari et al., 2016). Previous authors have reported live
birth as a secondary outcome measure in smaller and more heteroge-
neous studies (Harb et al., 2013). Since we only included women who
had laparoscopy to exclude endometriosis in the unexplained subferti-
lity group, our study overcomes the diagnostic limitation of other trials,
which included heterogeneous comparator groups. Our study
reported on treatment outcomes only for the first cycle of IVF treat-
ment to limit repeat observations that would introduce bias. We
acknowledge that it would have been ideal to assess the cumulative
live birth per cycle started since this would be more clinically relevant
to current practice as cryopreservation protocols have significantly
improved over the years. However, due to Health Authority funding
policy variations in the UK, this was not possible to ascertain in this
study because not all patients were in a position to utilize cryopreser-
vation of embryos.
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The study demonstrates that endometriosis impacts negatively on
the chance of a live birth in a ‘dose-response relationship’ as the effect
is more pronounced with increasing severity of disease based on the r-
ASRM staging system (ASRM, 1997). It appears that endometriosis
affects all aspects of IVF outcomes including folliculogenesis, embryo
development and implantation. It is postulated that impaired folliculo-
genesis results from an abnormal intra-ovarian cytokine milieu that
may also cause perturbations in endometrial decidualisation (Garrido
et al., 2000; Sallam et al., 2006). In this study, we demonstrate the
association between endometriosis and reduced follicular recruitment,
decreased likelihood of blastocyst ET and impaired implantation.
These effects of endometriosis are therefore not only restricted to
ovarian function but include endometrial function. The distribution of
various disease stages of endometriosis was well balanced in the
cohort, negating any bias for selecting cases with more severe disease
and skewing the observations. However, it appears the impact of
endometriosis becomes more apparent with increasing disease sever-
ity. The exact mechanism behind this effect is unknown, however, it
has been observed that donor oocytes from women with endometri-
osis have a lower developmental potential and achieve lower
pregnancy rates when given to women without endometriosis, an
effect which cannot be explained entirely by a difference in ovarian
reserve (Garrido et al., 2002). Such oocytes have also been reported
to have abnormal cytoskeletal and molecular characteristics (Da Broi
et al., 2014). It has been shown both in human and in animal models
that oocytes exposed to endometriosis had reduced potential to form
blastocyst embryos and demonstrated a higher rate of blastomere
apoptosis and developmental arrest (Da Broi et al., 2014; Xu et al.,
2015). Several mechanisms are thought to underlie these observations
including abnormal nitric oxide activation, formation of reactive oxygen
species and lipid peroxidation, and an abnormal cytokine milieu (Goud
et al., 2014; Dong et al., 2013; Stilley et al., 2012). It is also possible
that the presence of endometriosis may have epigenetic effects on the
oocyte resulting in alterations in the expression of genes responsible
for aromatase synthesis in cumulus cells, leading to reduced intrafolli-
cular oestradiol production (Baumann et al., 2015; Hosseini et al.,
2016). This cumulus–oocyte cross talk is essential for cytoplasmic and
nuclear maturation of the oocyte to render it competent.
Reduced implantation in women with endometriosis compared to
those with unexplained subfertility points towards altered endometrial
.............................................................................................................................................................................................
Table I Baseline characteristics of women with endometriosis and unexplained subfertility
Characteristics Endometriosis (n = 531) Unexplained (n = 737) P-value
Mean (95% CI) Mean (95% CI)
Median Age (years, range) 35 (23–44) 36 (19–44) <0.0001
BMI (Kg/m2) 23.4 (23.1–23.7) 23.9 (23.6–24.2) 0.04
median FSH (range) IU/ml 6.3 (1.5–15.4) 6.7 (2.2–17.6) 0.53
Baseline FSH (%) Stage 1 Stage 2 Stage 3 Stage 4 Non-exposed 0.03
<10 IU/ml 102 (19.2) 71 (13.4) 94 (17.7) 84 (15.8) 458 (62.7)
≥10 IU/ml 39 (7.3) 43 (8.1) 38 (7.2) 60 (11.3) 273 (37.3)
Duration of Infertility (Years) 3.9 (3.5–4.3) 3.6 (3.3–3.9) 0.08
Previous Live Birth (%) 56/531 (10.7) 99/737 (13.5) 0.2
Partner’s Sperm Count (×106 per ml) 66.6 (62.5–70.8) 74.8 (70–79.7) 0.01
.............................................................................................................................................................................................
Table II Response to controlled ovarian stimulation, fertilization and embryo development for cases with endometriosis
and unexplained subfertility
Characteristics Endometriosis (n= 531) Unexplained (n = 737) P-value
Mean (95% CI) Mean (95% CI)
Duration of Stimulation (Days) 11 (10.8–11.2) 11.2 (11–11.4) 0.92
Total Gonadotrophin Dose (Units) 2504.18 (2400.21–2608.15) 2214.37 (2142.08–2286.65) <0.0001
Total Oocytes Retrieved 9.15 (8.69–9.6) 10.54 (10.13-0.95) <0.0001
Mature Oocytes (MII) 7.56 (7.16–7.96) 8.84 (8.48–9.2) <0.0001
Number Fertilized (2PN) 5.96 (5.6–6.3) 6.6 (6.3–6.9) 0.07
Percentage fertilization 78.8 (77.6–80.1) 74.7 (73.6–75.7) <0.0001
Development at Embryo Transfer (%)
Cleavage Stage 462 (86.96) 460 (62.43) <0.001
Blastocyst Stage 69 (13.04) 277 (37.57)
N/S = not significant, MII: metaphase II, PN: pronucleii. Chi-square test for categorical and Student’s t-test for continuous data.
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function. This observations were also made by previous authors and
seem to be more pronounced in women conceiving by ART (Omland
et al., 2005). Basic science studies demonstrate abnormal inflammation-
mediated oestradiol production and progesterone resistance, rendering
the endometrium less receptive in endometriosis (Bulun et al., 2010).
Whereas other studies demonstrated increased risk of miscarriage in
women with endometriosis, we were unable to show this effect (Santulli
et al., 2016). Rather surprisingly, women with endometriosis had
reduced odds of miscarriage compared to those with unexplained sub-
fertility [OR 0.62 (95% CI, 0.43–0.89), P = 0.009]. It may well be that
women with unexplained subfertility were older than those with endo-
metriosis, this being a known risk factor for miscarriage. This finding
should be interpreted with caution as the study was not powered for
this outcome.
The global effects of endometriosis at both ovarian and endometrial
levels have been shown to be mitigated by long-term suppression of
pituitary function with GnRH analogs before IVF treatment to improve
outcomes (Sallam et al., 2006). Whereas this is a promising develop-
ment, more focussed research is urgently needed, particularly to eluci-
date the mechanisms underlying endometrial dysfunction in women
with endometriosis. Implantation failure does not appear to be over-
come by double ET and certainly the risk of multiple births cannot be
overlooked. Other ways of improving embryo selection, such as use of
morphokinetic parameters by time-lapse technology, need to be
urgently evaluated in similar studies in the future. (Bhide et al., 2017).
Conclusion
We have demonstrated that endometriosis reduces the chance of a
live birth in women undergoing ART, an effect that is more pro-
nounced with increasing disease severity. The effects of endometriosis
are associated with both reduced oocyte quality and embryo develop-
mental potential, as well as reduced implantation. Whereas ART has
proved effective in overcoming subfertility in many couples, research is
urgently needed in techniques that could further improve treatment
outcomes in women with endometriosis.
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Table III Bivariate analysis comparing IVF treatment outcomes between women with endometriosis and the non-
exposed group
Outcome Endometriosis (%) Unexplained (%) Crude OR (95% CI) P-value
Live birth rate 128 (24.1) 217 (29.4) 0.76 (0.59–0.98)a 0.035
Gestation at birth
≥37Weeks 109 (85.2) 187 (86.2) 0.09 (0.58–2.02) 0.46
<37Weeks 19 (14.8) 30 (13.8)
Clinical pregnancy rate 142 (26.7) 220 (29.9) 0.86 (0.67–1.1) 0.23
Miscarriage rateb 50/183 (27.3) 173/392 (44.1) 0.62 (0.43–0.89) 0.009
Positive pregnancy test 183/531 (34.5) 392/737 (53.2) 0.65 (0.53–0.8) <0.0001
Implantation Rate Per Embryo Transferred (%) 37.6 (33.5–41.8) 45.3 (41.7–48.9) 0.73 (0.58–0.92) 0.007
Ectopic pregnancy 5 2 5.36 (1.03–27.86) 0.046
Birth per embryos
transferred
Embryo(s) transferred No birth Single Twin Triplet No
birth
Single Twin Triplet
1 51
(78.5)
13 (20) 1
(1.5)
0 76
(54.3)
61
(43.6)
3
(2.1)
0 0.31 (0.16–0.58) 0.0002
2 264
(70.8)
88
(23.6)
21
(5.6)
0 252
(62.2)
118
(29.1)
32
(7.9)
3 (0.7) 0.72 (0.38–1.36) 0.32
3 25
(83.3)
4
(13.3)
0 1 (3.3) 12
(100)
0 0 0 n/a
aMultivariable stepwise logistic regression analysis (adjusted for age, ovarian reserve (FSH), endometriosis stage, number of mature oocytes and embryo developmental stage)
adjusted OR 0.76 (95% CI 0.56–1.03), P = 0.08.
bIncludes both biochemical and clinical miscarriage.
n/a = not applicable.
........................................................................................
Table IV Odds ratio for live birth with endometriosis
disease severity
Endometriosis status OR 95% CI P-value
aUnexplained 1
Minimal endometriosis 0.89 0.6–1.33 0.58
Mild endometriosis 0.65 0.4–1.04 0.07
Moderate endometriosis 0.87 0.57–1.31 0.5
Severe endometriosis 0.56 0.35–0.87 0.009
aWomen with unexplained infertility are the reference group.
Score test for trend of odds P = 0.008.
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